Mizuho Bank, Ltd., The Bank of Tokyo-Mitsubishi UFJ, Ltd.
Nippon Zenyaku Kogyo Co., Ltd. Keio Innovation Initiative, Inc. DBJ Capital Co., Ltd.
We will contribute to our society and global health by research, development and commercialization of
innovative medicines for patients suffering from incurable diseases.
Research & development of HGF (pharmaceuticals for regenerative medicine) Research & development of NK4
(pharmaceuticals for cancer therapy)
NK4 is a molecule, discovered by Professors Toshikazu Nakamura and Kunio Matsumoto, that inhibits tumor
angiogenesis and cancer metastasis. It is an innovative technology that holds malignant tumors at the stage of
freeze or dormancy. Kringle Pharma, Inc. was established as a pharmaceutical biotechnology venture company
originating from Osaka University in December 2001 with the goal of early development of new cancer therapies
utilizing NK4. Professors Nakamura and Matsumoto, who discovered NK4, became deeply engaged in the establishment
of Kringle Pharma, Inc. Professor. Matsumoto is the Chief Scientific Officer for the company, from October 2002
to November 2013.
Kunio Iwatani, Chairman of Kringle Pharma, Inc., was previously engaged in the expansion of business for the
International Division of Takeda Chemical Ind. Ltd. for nineteen years. After holding the positions of President
and CEO of Hokuriku Seiyaku Co. Ltd. and Director of Abbott Japan Co. Ltd. successively, he filled the position
as President and CEO from March 1, 2003 to December 16, 2016.
Kiichi Adachi, President and CEO of Kringle Pharma, Inc., was previously Postdoctoral Research Associate at
Purdue University before joining Paradigm Genetics, Inc. in NC, USA. He came back to Japan to join Biotechnology
Center of Mitsui Global Strategic Studies Institute as Chief Strategist. He joined Kringle Pharma, Inc. in April
2004 and served as Director of R&D, and subsequently Director of Business Development before being appointed to
his present position in December 16, 2016.
Kringle Pharma, Inc.
207 Saito Bio Incubator 7-7-15
Saitoasagi, Ibaraki, OSAKA
When using public transportation
Osaka Monorail Saito Line (International Culture Park City Monorail Line) Get off at Saito Nishi Station,
about 8 minutes on foot
The time required: About 17 minutes from Senri-Chuo Station